CompletedPhase 3

DSUVIA Early Evaluation of Pain Trial

United States150 participantsStarted 2022-08-05

Plain-language summary

Randomized, interventional trial of Emergency Department (ED) administration of DSUVIA (sufentanil) versus standard care pain management comparing pain treatment outcomes in injured patients with moderate to severe pain

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Trauma activation (Level I, II or III)
✓. Age 18-70 years inclusive
✓. Need for pain treatment based upon NRS (0-100) clinical pain measurement ≥ 50
✓. Estimated time in Emergency Department \> 30 minutes following informed consent

Exclusion criteria

✕. Advanced airway management prior to 1st dose administration
✕. Known allergy to opioids
✕. Known prisoner
✕. Known pregnancy
✕. ED pain medication contraindicated
✕. Significant respiratory depression
✕. Known or suspected gastrointestinal obstruction, including paralytic ileus

What they're measuring

Verbally Administered Numeric Rating Scale (VNRS)

Timeframe: 30 minutes after administration

Trial details

NCT IDNCT05288348

SponsorFrank Guyette

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-01-21

Results submitted2025-01-21

View on ClinicalTrials.gov More Traumatic Injury trials